Hippocratic AI, based in California and specialising in safety-focused LLMs for healthcare’s non-diagnostic, patient-facing clinical tasks, raises $141M in Series B funding. Kleiner Perkins led the round, with participation from existing investors — A16z, General Catalyst, Premji, NVIDIA, SV Angel, Universal Health Services (UHS), and WellSpan Health — all maintaining or increasing their stakes.
The Series B round, which closed nine months after Series A, valued Hippocratic AI at $1.64 billion, earning it “unicorn” status. With this capital, the company plans to expand into pharmaceuticals and the payor space while entering new markets in Europe, the Middle East, Africa, Southeast Asia, and Latin America.
Hippocratic AI: introducing empathy inference for healthcare
Founded in 2024 in Palo Alto by Munjal Shah (who sold Like to Google in 2010), Vishal Parikh, Meenesh Bhimani, Subho Mukherjee, and Saad Godil, the company tackles healthcare’s challenges: staff shortages, accessibility, AI safety, patient care quality, and system transformation. Its core technology, Polaris, is a safety-focused LLM constellation architecture for healthcare. This system creates AI agents that conduct natural conversations with patients about non-diagnostic topics, like dietary recommendations and medication schedules.
Unlike its competitors, Hippocratic AI prioritises patient safety. Its models undergo extensive safety testing and follow strict healthcare ethical guidelines. In collaboration with NVIDIA, it developed Empathy Inference, a technology for swift, natural conversations that forge emotional connections with patients.
“The last nine months have been a very productive period at the company. We raised our Series A with the support of Premji and NVIDIA; released our Polaris 2.0 architecture; expanded our nurse, physician, and industry advisory councils; received our first US patent; achieved safety parity of our AI agents with human clinicians; signed contracts with 23 health systems, payors, and pharma clients in just 23 weeks; launched 16 of those clients; and received a positive reception from patients,” said Munjal Shah, co-founder and CEO of Hippocratic AI.
The company recently partnered with Arkos Health, Belong Health, Cincinnati Children’s, Fraser Health (Canada), GuideHealth, Honor Health, Ideal Dental, Nsight Health, OhioHealth, VNS Health, UHS, WellSpan Health, and others. Their GenAI agents conducted hundreds of thousands of patient calls, earning an average rating of 8.7 out of 10.
The debut of the AI agent App Store
Alongside the funding news, Hippocratic AI unveiled its AI Agent App Store—a breakthrough platform for clinician-driven healthcare AI development. This user-friendly system lets healthcare professionals create customised AI agents for specific medical needs and workflows in under 30 minutes without coding experience.
The store debuts with over 300 AI agents across 25 medical specialities, handling tasks from cervical cancer check-ins to postpartum mental health support, wound care, and diabetes screening. Each agent undergoes thorough safety and efficacy verification through a three-step process, including licensure verification, development testing, and validation by over 6,000 nurses and 300 doctors.
The future of medicine depends on ethical AI
“The total addressable market for using generative AI to solve healthcare staffing shortages is probably 10 times the healthcare software market, and we’re excited to support the Hippocratic AI team,” said Mamoon Hamid, Partner, Kleiner Perkins.
The future of medicine is intertwined with the ethical development and deployment of AI technologies. The challenge lies in balancing innovation with responsibility, ensuring that medical AI serves patients’ and society’s best interests.
The post NVIDIA, A16z-backed Hippocratic AI achieves unicorn status with a $141M round to deploy clinical AI agents in hospitals appeared first on Tech Funding News.